September 25, 2017 4:14 AM ET


Company Overview of Humanigen, Inc.

Company Overview

Humanigen, Inc., a biopharmaceutical company, focuses on developing medicines for patients with neglected and rare diseases with focus on pediatric conditions in the United States. The company’s lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal, and neurological problems. It is also developing proprietary monoclonal antibodies, including lenzilumab, which is in Phase 1/2 clinical trial in patients with chronic myelomonocytic leukemia, and potentially for the treatment of juvenile myelomonocytic leukemia; and ifabotuzumab that has completed the Phase I dose escalation portion of a Phase I/II clinical tr...

1000 Marina Boulevard

Suite 250

Brisbane, CA 94005

United States

Founded in 2000

17 Employees



Key Executives for Humanigen, Inc.

Chairman & CEO
Age: 57
Total Annual Compensation: $500.0K
Chief Scientific Officer
Age: 52
Total Annual Compensation: $427.5K
Compensation as of Fiscal Year 2016.

Humanigen, Inc. Key Developments

Humanigen, Inc. Appoints Greg Jester as Chief Financial Officer, Effective September 5, 2017

Humanigen, Inc. announced it has appointed Greg Jester as its chief financial officer (CFO), effective September 5, 2017. Mr. Jester brings more than two decades of financial, operational management and entrepreneurial experience in the life sciences industry. He will be responsible for further strengthening Humanigen’s financial foundation to facilitate the company’s next growth phase. Most recently, Mr. Jester served as vice president, finance, for Tris Pharma.

Humanigen, Inc. Announces Executive Changes

Humanigen, Inc. appointed Cameron Durrant as the Company's interim Chief Financial Officer, until a new Chief Financial Officer is in place. Dr. Durrant succeeds David L. Tousley, who resigned as the Company's interim Chief Financial Officer effective August 11, 2017.

Humanigen, Inc. Announces Completion of Benznidazole Bioavailability Study

Humanigen, Inc. announced that it has completed enrollment and follow-up of subjects in its human bioavailability study for benznidazole. The bioavailability study is a key part of the company’s planned New Drug Application (NDA) package to the U.S. Food and Drug Administration (FDA) in the 505(b)(2) development program for benznidazole as a potential treatment for Chagas disease, a neglected tropical disease. The study’s main objective is to characterize the pharmacokinetic profile of benznidazole. Analysis of the study has begun and the company anticipates preliminary interpretation of the data by October. The company expects to have the final study report in the fourth quarter of this year. The company expects to submit its NDA in the first quarter of 2018. The company received clearance from the FDA in June for its Investigational New Drug (IND) application and earlier this year received positive guidance from the FDA supporting the company’s proposed 505(b)(2) regulatory pathway for benznidazole, enabling the company to use data obtained from previously conducted studies to demonstrate safety and efficacy in the treatment of Chagas disease within the U.S.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
August 23, 2017
Private Placement
December 21, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Humanigen, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at